Based on the firm’s proprietary HIFI platform, the new solution can detect six high-risk and high-incidence cancers in China, including lung cancer, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, and colorectal cancer
HIFI Pan-Cancer Screening uses whole-genome sequencing (WGS) of cell-free DNA (Credit: Pete Linforth from Pixabay)
Genomic testing and early cancer screening firm Berry Oncology has launched HIFI Pan-Cancer Screening, a multi-cancer early screening product for identifying six high-risk cancers at one time.
Based on the firm’s proprietary HIFI platform, the new solution can detect six high-risk and high-incidence cancers in China, including lung cancer, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, and colorectal cancer.
Berry Oncology said that the screening product has a sensitivity of 87.58%, specificity of 99.09%, and traceability accuracy of 82%.
According to the company, NGS-based liquid biopsy technology offers improved overall testing performance, benefits of minimal invasiveness and user-friendliness.
In comparison to conventional cancer screening techniques, the technology increases the compliance of high-risk groups and expands the clinical intervention window for patients with early-stage cancer to enhance their survival rate.
According to the firm, HIFI Pan-Cancer Screening is the first early screening product in the world for multiple cancer types that uses whole-genome sequencing (WGS) of cell-free DNA (cfDNA).
It can detect early cancer signals in a broader range and minimise missed cancer detection due to individual variances and variations in the molecular biology of several tumour types.
The company said that self-iterative HIFI technology platform can reduce the costs of product development and testing services, making early screening for multiple cancers more affordable.
Berry Oncology CEO Zhou Jun said: “Since its establishment, Berry Oncology has been dedicated to developing technologies and delivering products for early cancer screening based on the spectrum of malignant tumours, to help more high-risk people identify hidden risks and help more patients prolong survival time and improve quality of life.
“Moving forward, Berry Oncology will continue to optimise its technology system and iterate early screening products to deliver more advanced early cancer screening solutions in accordance with the actual market demand and environment.
“In the meanwhile, we will further our partnerships with industry players, universities and research organisations to co-build an ecosystem for cancer prevention and treatment that enables innovations more accessible.”